TY  - JOUR
AU  - Ali, Esraa
AU  - Trailin, Andriy
AU  - Ambrozkiewicz, Filip
AU  - Liška, Václav
AU  - Hemminki, Kari
TI  - Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies.
JO  - International journal of molecular sciences
VL  - 23
IS  - 23
SN  - 1422-0067
CY  - Basel
PB  - Molecular Diversity Preservation International
M1  - DKFZ-2022-03039
SP  - 15292
PY  - 2022
N1  - #LA:C020#
AB  - Hepatocellular carcinoma (HCC) is a global healthcare challenge, which affects more than 815,000 new cases every year. Activated hepatic stellate cells (aHSCs) remain the principal cells that drive HCC onset and growth. aHSCs suppress the anti-tumor immune response through interaction with different immune cells. They also increase the deposition of the extracellular matrix proteins, challenging the reversion of fibrosis and increasing HCC growth and metastasis. Therapy for HCC was reported to activate HSCs, which could explain the low efficacy of current treatments. Conversely, recent studies aimed at the deactivation of HSCs show that they have been able to inhibit HCC growth. In this review article, we discuss the role of aHSCs in HCC pathophysiology and therapy. Finally, we provide suggestions for the experimental implementation of HSCs in HCC therapies.
KW  - fibrosis regression (Other)
KW  - hepatic stellate cells (Other)
KW  - hepatocellular carcinoma (Other)
KW  - therapeutic studies (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36499616
DO  - DOI:10.3390/ijms232315292
UR  - https://inrepo02.dkfz.de/record/186245
ER  -